

Shire buys US biotech firm Dyax for \$5.9bn: companies

November 2 2015

Dublin-based pharmaceutical group Shire said Monday it had agreed to buy Dyax, a US company specialising in rare diseases, for \$5.9 billion (5.34 billion euros).

"This highly complementary transaction aligns with and accelerates our strategy to build a global leading biotechnology company focused on [rare diseases](#) and speciality conditions," Shire's chief executive Flemming Ornskov said in a statement outlining the deal that could rise by a further \$650 million.

Dyax's chief executive, Gustav Christensen, said the "transaction will deliver substantial value" to his company's shareholders amid a sustained period of sector consolidation.

He added that the deal highlights Dyax's "shared commitment to bringing innovative medicines to patients who suffer from the devastating effects of HAE"—described in the statement as a "rare, debilitating genetic inflammatory condition".

London-listed Shire, which is betting on success for Dyax's DX-2930 test drug treatment for HAE, added that it had not given up on trying to buy US biotech firm Baxalta in a much bigger deal.

"Even with this (Dyax) transaction, we will continue to have the financial firepower to pursue other value-added strategic acquisitions, including Baxalta," Ornskov said in Monday's statement.

Shire had a \$30-billion offer for Baxalta turned down by the US group in August.

© 2015 AFP

Citation: Shire buys US biotech firm Dyax for \$5.9bn: companies (2015, November 2) retrieved 7 May 2024 from <https://medicalxpress.com/news/2015-11-shire-biotech-firm-dyax-59bn.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.